Boston Scientific (BSX) to Release Earnings on Wednesday

Boston Scientific (NYSE:BSX - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Wednesday, July 23rd. Analysts expect the company to announce earnings of $0.72 per share and revenue of $4.89 billion for the quarter. Boston Scientific has set its FY 2025 guidance at 2.870-2.940 EPS and its Q2 2025 guidance at 0.710-0.730 EPS.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The company had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same period last year, the firm earned $0.56 earnings per share. The firm's revenue was up 20.9% on a year-over-year basis. On average, analysts expect Boston Scientific to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Boston Scientific Stock Down 0.9%

Shares of BSX traded down $0.97 during trading hours on Friday, reaching $103.68. 8,571,099 shares of the stock traded hands, compared to its average volume of 6,759,200. The company has a current ratio of 1.45, a quick ratio of 0.88 and a debt-to-equity ratio of 0.47. The stock has a fifty day simple moving average of $103.40 and a 200 day simple moving average of $100.90. Boston Scientific has a 52 week low of $71.88 and a 52 week high of $107.53. The company has a market cap of $153.39 billion, a price-to-earnings ratio of 75.68, a PEG ratio of 2.72 and a beta of 0.68.

Analyst Ratings Changes

A number of research analysts recently weighed in on BSX shares. Barclays raised their price target on shares of Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Wall Street Zen upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Morgan Stanley raised their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, May 16th. Evercore ISI raised their price objective on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Finally, BTIG Research restated a "buy" rating and set a $124.00 price objective on shares of Boston Scientific in a report on Wednesday, April 23rd. Twenty-two investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of "Buy" and an average price target of $116.09.

Insider Activity at Boston Scientific

In related news, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the transaction, the senior vice president owned 36,193 shares of the company's stock, valued at approximately $3,441,592.37. The trade was a 11.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,314 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the transaction, the executive vice president directly owned 22,235 shares of the company's stock, valued at approximately $2,269,304.10. This represents a 43.78% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 461,970 shares of company stock valued at $47,755,193 in the last quarter. 0.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Boston Scientific

An institutional investor recently raised its position in Boston Scientific stock. Brighton Jones LLC boosted its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 0.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,376 shares of the medical equipment provider's stock after acquiring an additional 226 shares during the period. Brighton Jones LLC's holdings in Boston Scientific were worth $2,445,000 as of its most recent SEC filing. Institutional investors own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.